Dunkirk’s state-of-the-art facility is expected to play a significant role in the production of a new cancer-fighting drug developed by ImmunityBio Inc. On Tuesday, the company announced in a news ...

DUNKIRK, N.Y. — ImmunityBio has filed a WARN notice with the New York state Department of Labor for two layoffs at its plant in Dunkirk. According to the notice, the California-based biopharmaceutical ...

A monumental achievement for ImmunityBio, Inc., occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. Earlier this week, the Food and Drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...

ImmunityBio has secured final local approval to restart its long-delayed Dunkirk, New York manufacturing facility, set to become a key U.S. hub for its cancer immunotherapy Anktiva. The project ...

Add Yahoo as a preferred source to see more of our stories on Google. The stalled Dunkirk pharmaceutical project is moving ahead with a new lease for ImmunityBio and tighter controls. John Travolta ...

ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...

As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...